SHUKRA
PHARMACEUTICALS LTD.

MEDIA RELEASE

Shukra Pharmaceuticals Limited Announces Direct Listing on National Stock Exchange (NSE); Trading to Commence on 14th August 2026

AHMEDABAD, INDIA – AUGUST 14, 2026 – Shukra Pharmaceuticals Limited (BSE: 524632), a prominent player in the pharmaceutical manufacturing sector, today announced that its equity shares have been approved for listing and regular trading on the Main Board of the National Stock Exchange of India Limited (NSE).

The company has marked this landmark milestone with the iconic ceremonial opening bell ringing at the NSE Exchange Plaza, Mumbai, on Friday, 14th August 2026.

This transition to the NSE represents a direct listing from the Bombay Stock Exchange (BSE), where the company's shares will continue to trade actively. The dual-listing strategy is aimed at expanding the company's visibility, attracting a broader base of institutional and retail investors, and deepening market liquidity.

To ensure precision in order routing and to assist institutional market participants in managing liquidity pipelines effectively, the trading identifiers for the equity shares on the NSE platform are detailed below:

- NSE Trading Symbol: SHUKRAPHAR
- International Securities Identification Number (ISIN): INE551C01044
- Market Segment: Main Board – Equity (Normal Rolling Market)
- Base Reference Price: Derived from the closing price of the equity shares on the BSE on August 13, 2026.

Growth & Expansion Focused

Mr. Dakshesh Shah, **Managing Director** of Shukra Pharmaceuticals Limited, said: *"Our listing on the National Stock Exchange of India marks a major milestone in our corporate journey. This step reflects our strong financial health and operational scaling. By trading on the NSE, we are expanding our reach to institutional investors and increasing market liquidity. This moves us closer to our goal of becoming a premier name in global pharmaceutical manufacturing. We are proud to see Shukra Pharmaceuticals enter India's premier equity platform. This direct listing is a testament to our transparent corporate governance and the trust of our shareholders on the BSE. As a dual-listed entity, we offer a more accessible platform for new investors. We remain committed to driving sustainable, long-term value for everyone involved."*

The company confirms that all relevant corporate disclosures, historical operational metrics, and the latest financial results have been filed uniformly under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, across both exchanges to prevent information asymmetry.

About Shukra Pharmaceuticals Limited:

Shukra Pharmaceuticals Limited is an India-based pharmaceutical company engaged in the manufacturing and marketing of a wide range of generic pharmaceutical formulations. Operating with state-of-the-art facilities compliant with current good manufacturing practices (cGMP), the company manufactures tablets, capsules, and liquid injections, catering to both domestic public healthcare demands and international distribution networks.

Media & Investor Relations Contact:

The Company Secretary / PR Desk

Shukra Pharmaceuticals Limited

Email: info@shukrapharmaceuticals.com
Website: www.shukrapharmaceuticals.com
Phone: +91 9909969543

Certificates, statements, or descriptions in this release that are not historical facts may constitute forward-looking statements. These involves risks, macroeconomic uncertainties, and regulatory variables that could cause actual operational outcomes to differ materially from those projected.

For **Shukra Pharmaceuticals Limited**

Dhakad

Shukra Pharmaceuticals Limited REG. NO.: 019079

Name: Shivkant Dhakad
Company Secretary
Phone: **+91 9909969543**
Email ID: info@shukrapharmaceuticals.com

14th August, 2026 at Mumbai